Back to Research Hub
Harmony Biosciences Holdings, Inc.
HRMY
$34.10+1.71 (+5.28%)
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
StreetsValue research for Harmony Biosciences Holdings, Inc. (HRMY)
Members get the full report for Harmony Biosciences Holdings, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.